|
Objective: To observe Tanshinone on coronary heart disease ( heart and blood stasis resistance type ) and do the preliminary efficacy in patients evaluated, and a preliminary investigation of its mechanism . Methods: meeting the inclusion criteria stable angina pectoris ( blood stasis type ) 60 patients were randomly divided into two groups, the treatment group of 30 people in the control group of 30 people. Admission routine examination , ECG changes were recorded and the required degree of biochemical , clinical symptoms were recorded . All patients were routinely used nitric acid lipid drugs, small doses of enteric-coated Aspirin forest, statin drugs , p -blockers for hypertension patients with ACEI or ARB therapy, do not use any products containing Salvia drugs. In the conventional treatment group therapy based on the use of tanshinone Ⅱ A sulfonate injection 60mg 5% glucose injection 150ml qdivgtt. Two weeks a course of treatment. During the periodic review electrocardiogram recorded after the end of treatment in patients with clinical symptoms, nitroglycerin stopped by rate , ECG changes , plasma ET-1 levels , etc., through statistical analysis, draw conclusions. Results: After treatment significantly effect the efficiency of the treatment group overall efficiency significantly higher (p lt; 0.05). Plasma ET-1 groups were significantly lower in the treatment group were also significantly lower (p lt; 0.05). Conclusions: 1 tanshinone Ⅱ A sulfonate injection can effectively ease angina ( blood stasis type ) , in reducing nitroglycerin usage, improving patient clinical symptoms , etc., significantly better than using western medicine . 2 tanshinone Ⅱ A sulfonate injection can significantly reduce plasma ET-1 levels , and more effective than simply using western medicine control group .
|